Synairgen plc Company Profile (LON:SNG)

About Synairgen plc

Synairgen plc logoSynairgen plc is the United Kingdom-based holding company for Synairgen Research Limited, a respiratory drug discovery and development company. The Company is engaged in the licensing of inhaled interferon beta (IFN-b) program to AstraZeneca. Synairgen has a BioBank consisting of blood, sputum, nasal lavage, biopsies, bronchial epithelial cells and fibroblasts from volunteers with asthma or chronic obstructive pulmonary disease (COPD) (and relevant controls). Using the BioBank, Synairgen has a number of tissue models, which include In vitro and Ex vivo models. IFN-b is offered for the treatment or prevention of asthma exacerbations caused by the common cold, and is in Clinical Phase II stage. IFN-b is provided for the treatment or prevention of COPD exacerbations caused by the common cold, and is in Clinical Phase I stage.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: LON
  • Symbol: SNG
  • CUSIP:
Key Metrics:
  • Previous Close: $0.42
  • 50 Day Moving Average: $34.30
  • 200 Day Moving Average: $30.49
  • 52-Week Range: GBX 19 - GBX 38
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $29.69M
  • Outstanding Shares: 91,340,000
Additional Links:

Analyst Ratings

Consensus Ratings for Synairgen plc (LON:SNG) (?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: GBX 91.50

Analysts' Ratings History for Synairgen plc (LON:SNG)
Show:
DateFirmActionRatingPrice TargetDetails
9/22/2016N+1 SingerLower Price TargetBuyGBX 47 -> GBX 46View Rating Details
9/22/2016FinnCapReiterated RatingCorporateGBX 137View Rating Details
(Data available from 9/28/2014 forward)

Earnings

Earnings History for Synairgen plc (LON:SNG)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Synairgen plc (LON:SNG)
Current Year EPS Consensus Estimate: $-3.57 EPS

Dividends

Dividend History for Synairgen plc (LON:SNG)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Synairgen plc (LON:SNG)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/11/2015Shaw,Simon J BInsiderBuy65,217GBX 23£14,999.91
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Synairgen plc (LON:SNG)
DateHeadline
proactiveinvestors.co.uk logoSynairgen on schedule with all of its drug programmes (LON:SNG)
www.proactiveinvestors.co.uk - September 22 at 7:01 PM
biz.yahoo.com logoHalf Year 2016 Synairgen PLC Earnings Release - Before Market Open (LON:SNG)
biz.yahoo.com - September 22 at 12:10 PM
capitalcube.com logoSynairgen Plc :SNG-GB: Earnings Analysis: 2015 By the Numbers : August 11, 2016 (LON:SNG)
www.capitalcube.com - August 11 at 10:48 AM
live-pr.com logoSynairgen Plc (SNG) - Financial and Strategic SWOT Analysis Review - New Market Report (LON:SNG)
www.live-pr.com - June 29 at 10:15 AM
4-traders.com logoSynairgen : Results of 2016 Annual General Meeting (LON:SNG)
www.4-traders.com - June 15 at 11:52 AM
capitalcube.com logoSynairgen Plc :SNG-GB: Earnings Analysis: 2015 By the Numbers (LON:SNG)
www.capitalcube.com - March 29 at 9:10 PM
biz.yahoo.com logoFull Year 2015 Synairgen PLC Earnings Release - Before Market Open (LON:SNG)
biz.yahoo.com - March 22 at 7:07 AM
publicnow.com logoPositive LOXL2 results (LON:SNG)
www.publicnow.com - March 22 at 3:45 AM
noodls.com logoSynairgen plc - Synairgen and Pharmaxis announce research collaboration to develop LOXL2 inhibitor for pulmonary fibrosis (LON:SNG)
www.noodls.com - August 5 at 9:04 AM
finance.yahoo.com logoPharmaxis and Synairgen Announce Research Collaboration to Develop LOXL2 Inhibitor For Pulmonary Fibrosis (LON:SNG)
finance.yahoo.com - August 5 at 12:02 AM

Social


Last Updated on 9/28/2016 by MarketBeat.com Staff